Results 241 to 250 of about 8,380,026 (270)
Some of the next articles are maybe not open access.
Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib
International Journal of Oral and Maxillofacial Surgery, 2020We report the case of a 71-year-old woman who developed advanced basal cell carcinoma (BCC) affecting the right eyebrow, invading the orbit. Globe displacement resulted in visual disturbances. Following multidisciplinary assessment, the tumour was deemed technically resectable for excision and right orbital exenteration.
P, Glen, D, Farrugia, J, Farrier
openaire +2 more sources
Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma
Dermatology, 2021<b><i>Background:</i></b> Vismodegib has shown clinical efficacy in the management of locally advanced basal cell carcinomas (laBCC). However, non-response to vismodegib is observed in 2–13.5% of patients in clinical studies. The purpose of this study was to identify factors associated with non-response to vismodegib in patients
Hélène Marescassier +8 more
openaire +4 more sources
Severe Necrotizing Locally Advanced Basal Cell Carcinoma With Osteomyelitis
Advances in Skin & Wound CareLocally advanced basal cell carcinoma (BCC) is an uncommon and complex presentation of BCC. These tumors can present as extensive nonhealing ulcers and require skin biopsy to rule out other causes, including malignant, infectious, and inflammatory etiologies.
Anjie Ge +3 more
openaire +2 more sources
Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma
Current Pharmaceutical Design, 2017Basal cell caricnoma (BCC), the most common periocular magliancy, is treated with complete surgical excision. However, in patients not amenable to surgery or when surgical resection means loss of vital organs or disfiguring procedures due to locally advanced or metastatic disease, targeting the hedgehog pathway offers a novel treatment approach for ...
Vivian T, Yin, Bita, Esmaeli
openaire +2 more sources
American Journal of Ophthalmology, 2015
To review our experience treating patients with the Hedgehog pathway inhibitor, vismodegib, in patients with orbital or periocular locally advanced or metastatic basal cell carcinoma (BCC) or basal cell nevus syndrome.Retrospective interventional case series.We reviewed all patients with locally advanced or metastatic orbital or periocular BCC or basal
Omar K. Ozgur +8 more
openaire +2 more sources
To review our experience treating patients with the Hedgehog pathway inhibitor, vismodegib, in patients with orbital or periocular locally advanced or metastatic basal cell carcinoma (BCC) or basal cell nevus syndrome.Retrospective interventional case series.We reviewed all patients with locally advanced or metastatic orbital or periocular BCC or basal
Omar K. Ozgur +8 more
openaire +2 more sources
Treatment of locally advanced basal cell carcinoma with vismodegib
Medicina Clínica (English Edition), 2023Noelia, Moreiras Arias +2 more
openaire +2 more sources
Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose
CutisBasal cell carcinoma (BCC) is the most common cancer in the world, and its incidence continues to rise. Known risk factors for BCC include chronic UV exposure, advanced age, and genetic predisposition. A large majority of BCC cases have an altered Hedgehog (Hh) signaling pathway.
Evan, Mak, Shannon, Buck
openaire +2 more sources
Journal of the European Academy of Dermatology and Venereology, 2013
AbstractBackgroundBasal cell carcinoma (BCC) is a tumour that relies mainly on aerobic energy assimilation for growth and depends on an extensive microvascular network to support adequate oxygen supply. In this tumour, higher expression levels of vascular endothelial growth factor (VEGF) has been described to correlate with increased microvessel ...
G, Gaitanis, I D, Bassukas
openaire +2 more sources
AbstractBackgroundBasal cell carcinoma (BCC) is a tumour that relies mainly on aerobic energy assimilation for growth and depends on an extensive microvascular network to support adequate oxygen supply. In this tumour, higher expression levels of vascular endothelial growth factor (VEGF) has been described to correlate with increased microvessel ...
G, Gaitanis, I D, Bassukas
openaire +2 more sources
Drugs, 2012
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
openaire +2 more sources
Vismodegib is the first Hedgehog pathway inhibitor to be approved in the US, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.
openaire +2 more sources
Locally advanced basal cell carcinoma associated with distinct gut microbiome signature
JDDG: Journal der Deutschen Dermatologischen GesellschaftClinical letter.
Oscar M. Moreno‐Arrones +7 more
openaire +3 more sources